



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/36, C07K 16/08, C12N 15/06, 5/20, C12P 21/08, G01N 33/569, 33/577, B01J 20/00, A61K 39/42, C07K 16/42, 14/02, A61K 39/29, 48/00	A1	(11) International Publication Number: WO 97/40164 (43) International Publication Date: 30 October 1997 (30.10.97)
(21) International Application Number: PCT/GB97/01161 (22) International Filing Date: 25 April 1997 (25.04.97) (30) Priority Data: 9608626.9 25 April 1996 (25.04.96) GB (71) Applicant (for all designated States except US): MUREX DIAGNOSTICS CORPORATION [BB/BB]; Whitepark House, White Park Road, Bridgetown, Barbados (BB). (72) Inventors; and (75) Inventors/Applicants (for US only): TEDDER, Richard, Seton [GB/GB]; UCL Medical School, Windeyer Building, Dept. of Virology, 46 Cleveland Street, London W1P 6DB (GB). IJAZ, Samreen [GB/GB]; UCL Medical School, Windeyer Building, Dept. of Virology, 46 Cleveland Street, London W1P 6DB (GB). FERNS, Ruth, Bridget [GB/GB]; UCL Medical School, Windeyer Building, Dept. of Virology, 46 Cleveland Street, London W1P 6DB (GB). (74) Agents: SILVESTON, Judith et al.; Abel & Imray, Northumberland House, 303-306 High Holborn, London WC1V 7LH (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: HEPATITIS B MONOCLONAL ANTIBODIES (57) Abstract A monoclonal antibody that is capable of binding specifically to wild type HBsAg and to at least two mutant forms of HBsAg may be used in an improved immunoassay for the detection of both escape mutants and wild type HBsAg and may be used for passive immunisation against HBV.		